Company Overview and News

 
Shriram EPC Limited - Appointment

2018-09-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHRIRAMEPC 532945

 
Shriram EPC Limited - Financial Result Updates

2018-08-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHRIRAMEPC 532945

 
Shriram EPC Limited - Updates

2018-08-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHRIRAMEPC 532945

 
Shriram EPC Limited - Shareholders meeting

2018-08-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHRIRAMEPC 532945

 
SAIL, Shipping Corp, BSE, SJVN results

2018-08-02 thehindubusinessline
Around 60 companies including Adlabs Entertainment, Bank of Maharashtra, BSE, Berger Paints, Bharat Gears, CG Power, CUMI, Den Networks, Entertainment Network, EIH Associated, Gujarat Alkalies, Kaya, KEC International, Laurus Labs, Nilkamal, Mangalam Cement, Rico Auto, SAIL, Savita Oil, Shriram EPC, Shipping Corp, Sical Logistics, SJVN, Taj GVK, TIL, Titan Company, VIP Industries and Zydus Wellness will declare their April-June quarter results on Friday.
SHRIRAMEPC 539056 BHARATGEAR ADLABS 532945 532714 532700 531335 ENIL 533137 DEN MANGLMCEM 520086 SICAL KEC 505688 502157 ZYDUSWELL

 
Shriram EPC Limited - Shareholders meeting

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHRIRAMEPC 532945

 
Shriram EPC Limited - AGM/Book Closure

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHRIRAMEPC 532945

 
Change of promoters atOrient Green Power

2018-07-11 thehindubusinessline
Our Bureau Orient Green Power will see a change in promoters, the company informed the exchanges on Wednesday.
SHRIRAMEPC 500116 IDBI 533263 532945 GREENPOWER

 
Shriram Transport shares plunge on worries over subsidiary’s NCDs

2018-07-04 thehindubusinessline
The share price of Shriram Transport Finance Corporation (STFC) witnessed its sharpest fall in 19 months on Wednesday as global research firm Jefferies said one of the company’s unlisted subsidiary, SVL Ltd, may have inadequate cash flows to service debt raised via non convertible debentures (NCDs).
511218 SHRIRAMEPC SRRQY 532945 MS SRTRANSFIN

 
Shriram Transport Finance says group firm will honour NCD repayment

2018-07-04 livemint
Bengaluru: Shriram Transport Finance Co Ltd (STFC) said on Wednesday group firm SVL Ltd has the wherewithal to honour repayment on non-convertible debentures (NCDs) guaranteed by it.
511218 SHRIRAMEPC SRRQY 532945 MS SRTRANSFIN

 
Shriram EPC Limited - Change in Director(s)

2018-06-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHRIRAMEPC 532945

 
Fortis Healthcare, Unitech results in focus

2018-06-08 thehindubusinessline
The boards of Shriram EPC and Metalyst Forgings will meet on Saturday to decide on the quarter as well as full-year financial results for the period ended March 31, 2018. Ambica Agarbathies & Aroma Industries, Blue Blends (I), Fortis Healthcare, ISMT, Konark Synthetic, Unitech and Zylog Systems are among companies that will consider financial results on Monday. Fortis Healthcare, which is facing bids from various players including the Munjal-Burman combine, will remain in focus.
532883 SHRIRAMEPC METALFORGE BLUBLND-B KONARKSY FORTIS 513335 532945 514128 ZYLOG 532843 502761

 
Shriram EPC gains on strong March-quarter results

2018-06-08 thehindubusinessline
Shriram EPC gained on strong March-quarter results. The stock climbed as much as 10.5 per cent to Rs 20.50, highest since June 1.
SHRIRAMEPC 532945

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...